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Coronary artery disease and heart failure carry concurrent risk for atrial ﬁbrillation and life-threatening ventricular arrhythmias. We review
evidence indicating that at therapeutic concentrations, ranolazine has potential for dual suppression of these arrhythmias. Mechanisms and
clinical implications are discussed.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Coronary artery disease and heart failure carry a dual risk for atrial
ﬁbrillation (AF) and life-threatening ventricular arrhythmias.
1–4
Medical management of these conditions is challenging because of
the complex and differing factors underlying arrhythmogenesis in
the atria and ventricles. The difﬁculty of the problem is underscored
by the fact that the main contemporary agents used for rhythm
control in AF can result in ventricular proarrhythmia including
torsade de pointes.
5 Drugs with Class IC effects of blocking peak
INa can cause myocardial depression, promote reentrant ventricular
tachycardia, and increase mortality in patients with coronary disease.
Anti-AF agents with the Class III action of blocking IKr, such as dofe-
tilide and sotalol, can precipitate torsade de pointes. The multi-
channel blocking agent amiodarone is currently widely employed, al-
though its use can be problematic due to the potential for signiﬁcant
extra-cardiac toxicity, particularly in lung and thyroid tissue.
6 Drone-
darone, a non-iodinated benzofuran derivative of amiodarone that
exhibits all four classes of antiarrhythmic action, was developed to
achieve a better safety proﬁle by eliminating the iodine moiety
and substituting a methanesulfanyl group.
7,8 Whereas most studies
have shown that dronedarone reduces mortality and morbidity in
patients with paroxysmal AF,
7 it increased rates of heart failure,
stroke, and death from cardiovascular causes in patients with per-
manent AF or moderate to severe heart failure.
9 Although the
exact basis for the increased risk in these patients is unclear, the po-
tential for negative inotropy related to L-type calcium channel block-
ade at the currently recommended dosage has been suggested.
Ranolazine was developed as an antianginal agent and was initially
thought to confer its therapeutic effects primarily through partial
inhibition of fatty acid oxidation.
10 These drug actions were gener-
ally observed at concentrations exceeding the plasma levels found
in clinical trials (.10 mM).
11 More recent evidence indicates that
the anti-ischaemic effects of ranolazine relate to its inhibition of
late INa, which, through an effect on reverse sodium–calcium ex-
change, improves diastolic compliance, thereby increasing coron-
ary artery blood ﬂow.
12 Subsequent experimental studies have
revealed a potent antiarrhythmic effect of ranolazine against both
atrial and ventricular arrhythmias.
12–15
Clinical evidence of ranolazine’s antiarrhythmic efﬁcacy has
emerged from the MERLIN-TIMI 36 (Metabolic Efﬁciency with
Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary
Syndrome–Thrombolysis in Myocardial Infarction 36) trial, which
enrolled 6560 patients and was directed to the treatment of myo-
cardial ischaemia in patients with non-ST elevation acute coronary
syndrome.
16 Ranolazine reduced the incidence of supraventricular
arrhythmias with a trend towards lowering the incidence of new-
onset AF across 6 days of continuous electrocardiographic record-
ings.
17 A subsequent analysis indicated that among patients with
paroxysmal AF, the overall burden tended to be lower with rano-
lazine than with placebo, with fewer AF-related adverse events.
18
Ranolazine has also been demonstrated to be superior to amiodar-
one in reducing the incidence of AF following coronary artery
bypass graph surgery
19 and in combination therapy to improve
conversion from recent onset AF over amiodarone alone.
20
Murdock et al.
21 recently reported in a case series that ranolazine
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doi:10.1093/europace/eus380can facilitate electrical cardioversion of AF in patients with
cardioversion-resistant AF. Further analysis of the ambulatory elec-
trocardiogram recordings from MERLIN TIMI-36 revealed that
ranolazine can suppress not only supraventricular arrhythmias
but also episodes of non-sustained ventricular tachycardia.
22
The main goals of the present review are to summarize knowl-
edge and discuss mechanisms of ranolazine’s effects on both atrial
and ventricular arrhythmogenesis.
Inﬂuence of ranolazine on atrial
and ventricular electrical
properties in the normal,
intact heart
Programmed electrical stimulation was employed in anaesthetized
canine and porcine models to evaluate the effects of intravenous
ranolazine on excitability, refractoriness, dromotropy, and vulner-
ability to AF and ventricular ﬁbrillation (VF).
23–27
Atrial electrical properties
Experiments in large animals demonstrated ranolazine’s potent
atrial effects,
24 consistent with ﬁndings in isolated tissue studies
by Antzelevitch and colleagues.
14,28,29 Speciﬁcally, signiﬁcant
effects on atrial refractoriness were found in each atrial site
tested, namely high right atrium, right atrial appendage, and poster-
olateral left atrium (Table 1). These changes occurred in a
non-frequency-dependent manner, in contrast to reports of IKr
blockade by agents such as dofetilide and d-sotalol and to results
expected with peak INa blockade and post-repolarization refrac-
toriness. The phenomenon of non-frequency dependence may
result from reverse frequency-dependent IKr inhibition coupled
with frequency-dependent peak INa inhibition. The magnitude of
the increase in atrial effective refractory period in atrial sites
(.20% increase from baseline) was greater than the effect on
the right ventricular endocardium (,10% increase from baseline).
No signiﬁcant changes were observed in atrial or ventricular dia-
stolic thresholds. Ranolazine increased median atrial conduction
time, a surrogate marker for conduction velocity, from high right
atrium to posterolateral left atrium in a frequency-dependent
manner in agreement with prior studies and consistent with inhib-
ition of peak INa in atrial tissue.
Atrial ﬁbrillation suppression
To test whether ranolazine alters susceptibility to AF, the muscar-
inic transmitter acetylcholine (ACh) was administered into the
pericardial space by percutaneous transatrial access.
24 This ap-
proach incorporates multiple sites of action including atrial
tissue, ganglionic plexi, and pulmonary veins, all of which have
been implicated clinically in atrial arrhythmogenesis. A signiﬁcant
reduction in AF duration (Figure 1) and tendency to suppress AF
re-initiation were observed following ranolazine administration.
Despite the QT prolongation associated with AF-cardioversion,
torsade de pointes was not observed. These results are likely indi-
cative of the effect of ranolazine on atrial conduction velocity due
to peak INa inhibition and are similar to the actions of other potent
sodium channel blockers, including ﬂecainide and propafenone, and
suggest that ranolazine affects factors that are important not only
in maintaining AF but also possibly in initiating AF.
Ranolazine reduced the dominant frequency of AF,
24 an index of
organization of AF and the propensity for successful deﬁbrilla-
tion,
30 in both the left and right atria. Consistent with previous
reports of AF in humans and in other animal models,
31 the domin-
ant frequency of AF in the left atrium was always greater than that
in the right atrial appendage, indicating that the drivers for AF in
................................................................................
Table 1 Ranolazine’s effects on atrial and ventricular
effective refractory periods
Site Median effective
refractory period
(milliseconds)
Interquartile
range
(milliseconds)
P value
High right atrium
Control 167 159–179 0.006
Ranolazine 202 183–231
Right atrial appendage
Control 158 136–164 0.002
Ranolazine 202 187–211
Posterolateral left atrium
Control 140 117–150 0.014
Ranolazine 163 143–193
Right ventricle
Control 253 243–260 0.006
Ranolazine 275 271–281
Reprinted from ref.
24 with permission from John Wiley & Sons.
Figure 1 Representative example of surface (lead V1) and
intracardiac electrograms (posterolateral left atrium, LA) at
12 min after atrial ﬁbrillation (AF) initiation demonstrating early
termination of AF by ranolazine. Note in the upper tracing
(control) that AF is characterized by low voltage and high fre-
quency. At the same time period, with ranolazine treatment,
the arrhythmia became more organized, followed by conversion
to sinus rhythm. (Reprinted from ref.
24 with permission from
John Wiley & Sons.).
R.L. Verrier et al. 318this model reside in the left atrium, where susceptibility to
ACh-induced changes in rotor dynamics is enhanced.
32 Ranolazine
did not change this relationship, despite decreasing dominant fre-
quency of AF in both atria.
The cellular and ionic mechanisms by which ranolazine reduces
ACh-mediated AF are likely multifold: (i) depression of INa-
dependent parameters, which reduces action potential upstroke,
and increases in diastolic threshold of excitation and post-
repolarization refractoriness; (ii) IKr inhibition, which counteracts
ACh-induced shortening of action potential duration; (iii) late INa
inhibition, which suppresses late phase 3 early after-depolarizations
and reduces ITi, thereby suppressing delayed after-depolarizations
and triggered activity.
14,33 Ranolazine at the concentrations
tested has minimum effect on ICa. The anti-AF capacity of ranola-
zine has also been shown by Lemoine et al.
34 in terms of suppres-
sion of occurrence of early after-depolarizations and triggered
activity in an animal model of LQT3 (SCN5A inactivation-impairing
mutation).
Ventricular effects
Surface electrocardiogram analysis
Ranolazine moderately prolonged the QTc interval in the intact
porcine model,
23 consistent with previous reports in dogs
35 but
to a larger extent than is observed in humans.
10,36 The drug did
not alter Tpeak–Tend interval, an index of transmural dispersion of
repolarization, a parameter identiﬁed in a canine wedge prepar-
ation to be attributable to differential effects on epicardial vs.
M cells.
14 These effects were at variance from d-sotalol, a selective
IKr blocker, despite prolongation of action potential duration and
the QT interval of the in-vitro-modelled electrocardiogram by
both drugs.
14
Electrophysiological testing
Ranolazine prolonged ventricular effective refractory period in the
porcine model by a mean of 40 ms over a large range of stimulation
strengths.
23 Schram et al.
35 had previously observed a mild but
non-signiﬁcant increase in effective refractory period in canines
at both low and high doses of ranolazine. The signiﬁcant changes
in effective refractory period detected by Kumar et al.
23 may be
attributable to the larger sample size.
Ranolazine caused substantial increases in the magnitude of the
depolarization threshold current needed to induce the repetitive
extrasystoles (RE) and VF (Figure 2).
23 Because the intensity of
the stimulus required to provoke either RE or VF is inversely pro-
portional to the intrinsic level of cardiac electrical heterogeneity,
these measures yield an index of dispersion of refractoriness.
37
The ventricular vulnerable period width has been shown to correl-
ate with dispersion of repolarization,
38 lending further support to
these observations and to interpretation of the electrophysiologic-
al effects of ranolazine described. Accordingly, ranolazine’s in-
crease in the RE and VF thresholds and reduction in vulnerable
period width may indicate its potential antiarrhythmic mechanism,
namely, reduction in the dispersion of repolarization and refrac-
toriness. These changes to the underlying myocardial substrate
may be complementary to ranolazine’s suppression of triggered ac-
tivity due to early after-depolarizations.
39 These ﬁndings are
further supported by the report that in remodelled canine hearts
with complete heart block, ranolazine suppressed drug-induced
torsade de pointes, with concomitant changes in beat-to-beat vari-
ability of repolarization.
40
Deﬁbrillation threshold testing
Ranolazine did not alter the 50% probability of successful ventricu-
lar deﬁbrillation (DFT50), likely as a consequence of the counter-
vailing inﬂuences of IKr and INa inhibition (Figure 2).
23 Notably, IKr
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Figure 2 Connected dot plots of the (A) repetitive extrasys-
tole (RE) (N ¼ 9), (B) ventricular ﬁbrillation (VF) (N ¼ 5), and
(C) 50% probability of deﬁbrillation (DFT50)( N ¼ 6) thresholds.
Each line represents an individual experiment, while the dia-
monds represent the means+SD. (Reprinted from ref.
23 with
permission from John Wiley & Sons.)
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ition would increase it. Ranolazine exerts minor inﬂuences on
peak INa at slow to moderate heart rates, but at short cycle
lengths in depolarized cells, as during VF, the drug may inhibit
peak INa more effectively. Use dependence and increased binding
at less negative, that is, at more depolarized, membrane potentials
is a typical characteristic of sodium channel blockers and should
also apply to ranolazine.
41 Enhanced peak INa inhibition during
VF is consistent with the ﬁnding that ranolazine reduces the dom-
inant frequency of VF, indicative of active tissue binding during VF
notwithstanding the absence of an inﬂuence on DFT50. The obser-
vation that ranolazine’s antiﬁbrillatory effect is not associated with
a signiﬁcant increase in ventricular deﬁbrillation threshold indicates
that the drug appears unlikely to affect the margin of safety for de-
ﬁbrillation. In light of the importance of this issue, further experi-
mentation is warranted including testing deﬁbrillation threshold
during acute myocardial ischaemia.
Antiﬁbrillatory effects of
ranolazine in the ischaemic heart
Ventricular effects during severe
coronary artery stenosis
Because ischaemic heart disease is associated with increased risk
for ventricular arrhythmias, the effects of ranolazine during
severe left anterior descending coronary artery (LAD) stenosis
were assessed in the intact porcine model.
25 Electrode catheters
allowed assessment of the effects of severe LAD stenosis on the
levels of VF threshold and T-wave alternans (TWA), a beat-to-beat
ﬂuctuation in the ST-segment and T-wave, which has been shown
to reﬂect susceptibility to malignant ventricular arrhythmias.
42
Ranolazine signiﬁcantly increased VF threshold not only in the
normal heart but more importantly during myocardial ischaemia,
when the effects occurred independently of changes in LAD coron-
ary blood ﬂow, which was controlled with a hydraulic occluder.
Duringnormalcoronaryarteryﬂow,blockadeofIKrandconsequent
prolongationofactionpotentialdurationcontributedtoincreasesin
VF threshold induced byboth ranolazine andthe IKr blocker E-4031.
However,duringseveremyocardialischaemia,E-4031wasproﬁbril-
latory, as it decreased VF threshold from control stenosis, whereas
ranolazine increased it. Importantly, TWA tracked the ranolazine-
and E-4031-induced changes in VF threshold during myocardial
ischaemia, that is, ranolazine decreased but E-4031 did not alter
TWA levels from the control stenosis (Figures 3 and 4).
25 Studies
involving assessment of lactate production by sampling coronary
venous efﬂuent or other methods involving wall motion abnormal-
ities and measurement of regional myocardial blood ﬂow with
microspheres are required to establish an effect of ranolazine on
metabolism during myocardial ischaemia.
Ranolazine’s effects on VF threshold and TWA levels indicate
signiﬁcant blunting of ischaemia-induced dispersion of repolariza-
tion and refractoriness.
25 TWA reﬂects spatiotemporal heterogen-
eity of repolarization between neighbouring myocardial regions, as
has been shown in investigations in intact large animals.
43,44 and in
patients with cardiomyopathy.
45 The effects of ranolazine and
Figure 4 T-wave alternans (TWA) during left anterior des-
cending coronary artery stenosis. The tracings with and without
ranolazine (A) or E-4031 (B) are continuous (left panels) and
with QRS-aligned superimposition (right panels). The
stenosis-induced TWA was suppressed by ranolazine but not
by E-4031. (Reprinted from ref.
25 with permission from Heart
Rhythm Society.)
Figure 3 Coronary stenosis resulted in a signiﬁcant increase in
T-wave alternans (TWA) level, which was signiﬁcantly reduced by
ranolazine (N ¼ 12). Numbers in the columns refer to the mean
levels of T-wave alternans (TWA) in microvolts. (Reprinted from
ref.
25 with permission from Heart Rhythm Society.)
R.L. Verrier et al. 320E-4031 on VF threshold and TWA reﬂect their direct inﬂuences on
the electrophysiological properties of the ventricular myocardium
and are not attributable to changes in coronary artery blood ﬂow
as stenoses were maintained at the same level before and after
drug administration. These results are consistent with ﬁndings
reported by Kloner et al.,
46 who showed in rats subjected to prox-
imal left coronary artery occlusion followed by reperfusion that
ranolazine at a dose consistent with inhibition of late INa exerts
a potent antiarrhythmic effect and is superior to sotalol or
lidocaine.
Ischaemia-induced atrial ﬁbrillation
Ischaemic heart disease is associated not only with increased risk
for malignant ventricular arrhythmias
2 but also for AF.
1,4 In patients
with acute coronary syndromes, the incidence of AF has been
reported to be 6–22% and is associated with increased short-
and long-term morbidity and mortality. Nattel and coworkers
27
provided experimental evidence indicating that atrial ischaemia
can create a substrate for maintenance of AF by increasing local
conduction slowing, leading to unidirectional block and reentry.
They found that the L-type calcium channel blocker diltiazem and
the beta-adrenergic receptor blocker nadolol were protective
but that peak INa and IKr inhibition with ﬂecainide and dofetilide,
respectively, were not effective.
26
Recently, we induced concurrent atrial and ventricular ischae-
mia to evaluate simultaneously the effects of antiarrhythmic
agents on vulnerability to AF and ventricular tachyarrhythmias.
47,48
Stenosis at the origin of the left circumﬂex coronary artery,
which supplies all three major branches to the left atrium,
namely, the proximal, intermediate, and distal arteries,
49 induces
signiﬁcant left atrial ischaemia (Figure 5). In a preliminary
report,
48 we found that ranolazine at a plasma concentration in
the clinical dose range completely suppressed the ischaemia-
induced reduction in AF threshold. This protective effect against
ischaemia-induced AF appears to be due to direct effects on
atrial electrical properties independent of coronary ﬂow, as this
variable was controlled.
We also demonstrated that ranolazine and dronedarone at low
dosages exhibit a synergistic, antiarrhythmic effect on vulnerability
to AF and ventricular tachyarrhythmias during concurrent atrial
and ventricular ischaemia.
47 Speciﬁcally, when low doses of
either agent were given alone, there was no protective effect,
but the drug combination prevented the ischaemia-induced fall in
AF threshold, reduced AF inducibility, and shortened AF duration
while decreasing T-wave heterogeneity, a clinically relevant
measure of susceptibility to life-threatening ventricular arrhyth-
mias. Overall, these ﬁndings are consistent with the discovery by
Burashnikov et al.
50 that ranolazine and dronedarone afford syner-
gistic antiarrhythmic actions with respect to AF susceptibility. The
clinical relevance of synergistic antiarrhythmic protection by the
combination of low doses of ranolazine and dronedarone is
under investigation in ‘A Study to Evaluate the Effect of Ranolazine
and Dronedarone When Given Alone and in Combination
in Patients with Paroxysmal AF’ (HARMONY) trial (NCT
01522651). The effect of the drugs on AF burden will be studied
Figure 5 Experimental setup. Upper left panel: left atrial (LA) and left ventricular (LV) epicardial electrocardiograms obtained prior to
balloon occlusion of the left circumﬂex (LCx) coronary artery to reduce ﬂow by 75% during atrial pacing at 150 beats/min. Upper right
panel: Induction of atrial ﬁbrillation (AF) by a 6-mA S2 test stimulus following the last S1 pacing stimulus. Note visible T-wave heterogeneity
compared to the uniform pattern observed in the upper left panel. Lower panel: Hydraulic balloon occluder positioned around the proximal
LCx coronary artery upstream of the Doppler ﬂow probe. Electrode catheters are afﬁxed to the left atrial appendage and left ventricular epi-
cardium within the atrial and ventricular regions supplied by the LCx. (Reprinted from ref.
47 with permission from Heart Rhythm Society.)
Ranolazine’s protection against atrial and ventricular ﬁbrillation 321in patients with implanted dual chamber programmable pace-
makers with AF detection capabilities.
Ionic basis for ranolazine’s
antiarrhythmic effects
The three most likely ion channel currents responsible for the
electrophysiological effects of ranolazine in the normal or ischae-
mic atrial and ventricular myocardium are late INa, peak INa, and
IKr
12 (Tables 2, 3). Analysis of excised atrial appendages from
patients with AF have implicated late INa inhibition,
51 while experi-
mental studies in canine isolated perfused atrial tissue have pro-
vided evidence that ranolazine’s antiﬁbrillatory effect in the atria
is attributable primarily to inhibition of peak INa.
14 At therapeutic
concentrations, ranolazine also inhibits the delayed rectiﬁer potas-
sium current (IKr),
12,14 which has been extensively investigated as a
target to suppress AF.
52 In isolated tissue studies, evidence sug-
gests that ranolazine’s combined action on peak INa and IKr cur-
rents may enhance its efﬁcacy in reducing susceptibility to AF, as
this combination of ion channel effects contributes to atrial-
selective reduction in AF vulnerability.
53
On a cellular level, it is likely, based on results of studies in iso-
lated single and multicellular preparations that ranolazine sup-
presses non-sustained ventricular tachycardia by inhibition of late
INa, which results in increase in repolarization reserve and suppres-
sion of triggered activity caused by early and/or delayed after-
depolarizations.
14 Inhibition of late INa may also be implicated in
ranolazine’s capacity to reduce or abolish TWA, which results
from mishandling of Ca2+ transients in the sarcoplasmic reticu-
lum.
42 Investigations in a canine heart failure model demonstrated
that ranolazine reversibly blocked diastolic intracellular Ca2+ ac-
cumulation and spontaneous Ca2+ release by late INa inhibition.
54
In terms of improvement in myocardial mechanical function, Love-
lock et al.
55 demonstrated in a murine model that diastolic dysfunc-
tion can be reversed by ranolazine, most likely resulting from a
direct inﬂuence on myoﬁlaments.
Itisunlikelythatranolazine’santiﬁbrillatoryeffectsinbothatrialand
ventricular tissue during myocardial ischaemia without overt proar-
rhythmia are solely due to inhibition of peak INa and IKr as ﬂecainide
and E-4031, potent inhibitors of peak INa and IKr, respectively, were
not protective during ischaemia, while ranolazine was antiﬁbrilla-
tory.
25,47 Inhibition of late INa, with consequent reductions in the
arrhythmogenic effects of intracellular calcium overload and
...............................................................................................................................................................................
Table 2 Effects of ranolazine on various ion channel currents
Ion channel current Preparation Potency (IC50, mM) Comments References
Peak INa Canine ventricular myocytes 294 Tonic block Undrovinas et al.
56
KPQ murine cardiomyocytes 135 Fredj et al.
57
HEK293 cells 428 Rajamani et al.
41
HEK293 cells 285 Zygmunt et al.
58
Late INa Canine ventricular myocytes 5.9 Tonic block Antzelevitch et al.
53
Canine ventricular myocytes KPQ 6.5 Undrovinas et al.
56
Murine cardiomyocytes 15 Fredj et al.
57
HEK293 cells 6.9 Wu et al.
59
Rabbit ventricular myocytes 16.5 Jia et al.
60
IKr Canine ventricular myocytes 11.5 Antzelevitch et al.
53
HEK293 cells 14.4 Wu et al.
59
INCX Canine ventricular myocytes 91 Antzelevitch et al.
53
tsA201 cells 1.7 Soliman et al.
61
Rabbit ventricular myocytes .100 Gilead, unpublished data
ICa,L Canine ventricular myocytes 296 Antzelevitch et al.
53
...............................................................................................................................................................................
Table 3 Effects of ranolazine on G protein-coupled receptors (GPCR)
GPCR Preparation Potency (Ki, mM) Comments References
a1 Rat salivary gland 8.2 Radioligand binding Zhao et al.
62
Rat liver 19.5
Rat ventricle 10.5
b1 Rat ventricle 8.6 Binding Zhao et al.
62
Rat heart 1.4 Letienne et al.
63
b2 Guinea pig lung 14.8 Binding Zhao et al.
62
Guinea pig lung 0.5 Binding Letienne et al.
63
DDT1MF-2 cells 9.0 Binding Gilead, unpublished data
R.L. Verrier et al. 322improvementinrepolarizationreserve,isaplausiblemechanismofthe
antiﬁbrillatoryeffects ofranolazine and freedomfromproarrhythmia.
Conclusions and future directions
Collectively,theseexperimentalstudiesinintactlargeanimalmodels
indicate thatattherapeutic concentrations,ranolazine exerts signiﬁ-
cantbeneﬁcialeffectsonelectrophysiologicalpropertiesofboththe
atria and ventricles, with greater effects on the former structure.
Ranolazine’s potent cardioprotective effects offer distinct advan-
tages over other contemporary agents, as proarrhythmia was
found not to be a factor in the MERLIN TIMI-36 clinical trial
16,17,22
and in these large, intact animal models. Rather, the agent provides
safe, dual protection against ischaemia-inducedatrialand ventricular
arrhythmias.
25,47 Ranolazine also reduces ischaemia-induced
TWA
25andT-waveheterogeneity,
47electrocardiographicphenom-
ena indicating risk for ventricular arrhythmogenesis. As TWA can
be assessed during routine exercise testing or ambulatory electro-
cardiogram monitoring,
42 it can be employed to gauge clinical rele-
vance of the experimental ﬁndings.
Notwithstanding this progress, there remains a need to explore
further the underlying mechanisms responsible for ranolazine’s
antiarrhythmic action, in particular, to understand better the po-
tential involvement of metabolic and antiischaemic inﬂuences in
ranolazine’s action. Also, it is important to study the effects of
the agents in models in which chronic disease is simulated by in-
farction and electrical and structural remodelling.
Several clinical trials are underway that address these issues in
populations with diverse indications, as referenced at www.
clinicaltrials.gov. Collectively, the information reviewed and heigh-
tened interest in this compound with its unique mode of action are
likely to contribute to important inroads in the management of
supraventricular and ventricular arrhythmias.
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